Former insider hits out at FDAs links with pharmaceutical industry

A former senior consultant with the Food and Drug Administration (FDA) has criticised the American regulator's close relationship with the pharmaceutical industry. Interviewed in this week's BMJ, he attacks the FDA's decision to allow the re-marketing of a controversial drug.

Dr Paul Stolley joined the FDA in July 2000 to look into the post-marketing safety of alosteron (Lotronex), a treatment for irritable bowel syndrome manufactured by GlaxoSmithKline. Within months he was writing to his superiors about a rising toll of adverse incidents, including ischaemic colitis, hospitalisation, surgery, and deaths.

Glaxo Wellcome (as the company was then) voluntarily withdrew alosteron in November 2000, but almost immediately patient groups were pushing for its return. Stolley claims that his superior, Dr Janet Woodcock, accused him of "brow-beating" colleagues about the drug's risks. He also says other colleagues concerned about the drug's safety were pressurised to "help get this drug back on the market". Woodcock, however, says that alosetron is an example of how difficult it is to provide access to a risky drug for those in greatest need. On Stolley himself she says: "It's our responsibility to be dispassionate and not develop emotionally based positions".

In April a special advisory committee recommended that alosetron be remarketed on the condition that it was prescribed only by specially certified doctors. Six weeks later, however, the FDA formally re-approved marketing based only on "physician self attestation of qualifications".

A number of the committee members are now publicly warning of a risk of more deaths and another withdrawal if the drug returns to the market later this year. What happens in America is likely to determine whether the company pursues approval for the drug elsewhere in the world.

Over the last ten years eight drugs have been approved by the FDA and subsequently withdrawn for safety reasons, pro

Contact: Steve Harman
BMJ-British Medical Journal

Page: 1 2

Related medicine news :

1. Former President George Bush joins leaders from cancer community to announce historic collaboration
2. Former NHLBI director Lenfant receives Lifetime Achievement Award
3. How links with tobacco industry may have influenced the publication of research on second-hand smoke
4. Study links racial and ethnic gap in youth violence to social factors
5. Study links sexual behavior, genetic factors to increased risk of kidney infection in women under 50
6. New UCLA study develops links between socioeconomic status and poor health
7. New study links lead exposure with increased risk of cataract
8. Leading tobacco manufacturer conceals links to tobacco research facility
9. New analysis links breastfeeding to reduced risk of childhood leukemia
10. Study links warm offices to fewer typing errors and higher productivity
11. UMHS study links gonorrhea, prostate cancer in men

Post Your Comments:

(Date:11/13/2018)... ... 13, 2018 , ... A survey by the publishers of ADC Review ... antibody therapies reached U.S. $ 4 billion. Approximately forty-five percent of this market included ... therapies (including ADCs) is expected to grow significantly, to U.S. $ 17 billion by ...
(Date:11/13/2018)... ... November 13, 2018 , ... ... awareness and use of naloxone, an opioid overdose reversal drug. Most states, including ... to individuals without a prescription. , A new study by ...
(Date:11/13/2018)... ... November 13, 2018 , ... Trumpet Behavioral Health ... Autism Spectrum Disorder. , Trumpet Behavioral Health (“Trumpet”) is pleased to announce the ... include: , Austin, TX; Cincinnati, OH; Columbus, OH; Dallas, TX; Fort Worth, TX; ...
(Date:11/13/2018)... ... November 13, 2018 , ... ... the Atolla Skincare System. The monthly subscription kit includes at home skin analysis ... uniquely for the user. Atolla’s proprietary algorithm formulates the serum to combat a ...
(Date:11/13/2018)... (PRWEB) , ... November 13, 2018 , ... ... & Construction (EPC) company, announced that it has been named to Boston Business ... for the third consecutive year. This time, Beaumont Solar, through significant ...
Breaking Medicine News(10 mins):
(Date:11/13/2018)... ... November 13, 2018 , ... Esker, ... cloud computing , today announced that LifeNet Health , a global ... cloud-based AP solution is integrated with the company’s SAP® software system. ...
(Date:11/13/2018)... ... November 13, 2018 , ... The best treatment for ... November 2018 issue of the American Journal of Sports Medicine. They say, with time, ... MD , does not necessarily agree with that strategy, at least when it involves ...
(Date:11/13/2018)... ... 2018 , ... Mount Sinai Health System announced today that ... public listing that valued the company at $85 million on the London Stock ... syndicate of health care institutional and industry investors, with participation from Mount Sinai. ...
Breaking Medicine Technology:
Cached News: